Introduction
Folic acid (folate, vitamin B9) is an essential nutrient that is involved in many metabolic pathways, including amino acid interconversions and nucleotide synthesis in normal and proliferating cells 1 . Folate receptor (FR), a family of glycosylphosphatidylinositol-linked proteins, captures folate and other ligands from the extracellular milieu and transports them inside the cell via a nondestructive, recycling endosomal pathway. Two membrane folate receptors (FRα and FRβ) and two soluble receptors (FRγ and FRδ) have been identified. Both FRα and FRβ are functional for highaffinity folate binding, although they can display some differences in their binding affinity for reduced folate cofactors or antifolates 2, 3 . Surprisingly, FR is expressed on few cell types. FRα is detected on the apical surfaces of several epithelial cells where it is inaccessible to parenterally administered folate conjugates. FRβ, in contrast, is expressed on activated macrophages. FRγ and FRδ have been difficult to detect in human tissues [3] [4] [5] [6] . Elevated expression of FRα occurs in many human malignancies, as in the case of ovarian, endometrial, renal, lung and breast carcinomas, especially when associated with aggressively growing cancers 2 . Non-mucinous ovarian cancer, which represents the majority of ovarian cancers, was the first tumor type to be associated with FR "over-expression" 7, 8 . Importantly, conjugation of molecules to folic acid does not normally interfere with the high affinity (K d o1 nmol/L) of folate for its receptor nor with its endocytosis into cells 9 . Folate conjugates undergo internalization via receptor-mediated endocytosis, delivering the folate-linked drugs with high affinity into the cell interior, and with a proper linker, the active drug can be released under the acidic condition in the endosome 10, 11 . Taken together, FR-targeted strategies could have a significant impact on cancer treatment for patients diagnosed with FR-positive (FRþ) disease.
BMS-753493 is a novel epothilone folate conjugate which is designed to target FR over-expressing tumors. As shown in Fig. 1 , a molecule of BMS-753493 contains an active epothilone, BMS-748285, a folate moiety, and a peptide linker with a disulfide bond tethering the epothilone piece. The mechanism of action of the epothilone folate conjugate is presumably through tight binding of the folate moiety to FRα receptor on the target cell surface, followed by endocytosis of the receptor-ligand complex, and subsequent cleavage of the linker to release the active epothilone. BMS-753493 demonstrated antitumor activity in various experimental mouse xenograft models where folate receptor was over-expressed 12 . By targeting the folate receptor, BMS-753493 is expected to provide preferential distribution of BMS-748285 into the FRþ tumors in comparison with FR negative (FR-) tumors or normal tissues, thereby improving the therapeutic index of cancer treatment. However, tissue distribution and tumor concentration of BMS-753493 and BMS-748285 relative to plasma and other normal tissue concentrations are unknown.
The goal of this study was to investigate the distribution of radioactivity after a single i. 
Animal models and tumors
Six-to eight-week old CD2F1 female mice were used in these studies. Mice were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN, USA) and maintained in a specific pathogen free facility at Bristol-Myers Squibb Research and Development with food and water ad libitum. All animal experiments were done under a protocol approved by the Bristol-Myers Squibb Animal Care and Use Committee.
A tumor brei (2%, w/v) of M109 and 98M109 tumor cells were inoculated in the subcutaneous space of the mouse right and left flank of CD2F1 mice, respectively. High expression of FRα in 98M109 cells has been detected and confirmed (unpublished data). The xenografts were allowed to grow for two weeks after inoculation before being used in these distribution experiments. The approximate size of each tumor was around 100 mg at the time of dosing. 
Quantitative whole-body autoradiography (QWBA)
The frozen carcasses were rapidly stored below -20 1C until embedment in an ice-cold solution of 2% carboxymethylcellulose with a microtome stage. They were then frozen in a dry icehexane bath at -70 1C for approximately 60 min, followed by an overnight at -20 1C. Whole-body sections were obtained in a Leica CM3600 crymicrotome (Leica microsystems, Nussloch, Germany) at 40 mm thick in the sagittal plane. Sections were captured on adhesive tape (Scotch Tape No. 8210, 3M Ltd., St. Paul, MN, USA) at -20 1C. Sections at various levels were collected to include the major tissues and tumor, and then were dried in the cryomicrotome at -20 1C for 48 h. The sections of each animal was mounted on a cardboard, covered with a thin plastic wrap, and exposed along with calibration 3 H-standards (range from 0.04 to 13 nCi/mg) to a 3 H-sensitive phosphor imaging plate (Fuji Biomedical, Stamford, CT, USA) in lighttight exposure cassettes for 3 weeks at room temperature in a lead shielding box. After exposure, the imaging plates were scanned using Fuji 3000 image acquisition system (Fuji Biomedical). The image files were processed using MCID TM image analysis software (v.7.0, Imaging Research, Inc., St. Catherines, Ontario, Canada) and a standard curve was constructed from the integrated response and the radioactivity concentrations of the ]-calibration standards. The concentrations of radioactivity were expressed as the mg equivalents of parent compound per gram sample (mg eq/g). A lower limit of quantification (LLQ) was applied to the data. The LLOQ were determined by using the radioactive concentration of background without tissues.
Tissue distribution and pharmacokinetics study of unlabeled BMS-753493 and BMS-748285
BMS-753493 or BMS-748285 was administered intravenously though tail vein injection at a dose level of 2.2 nmol/kg (4 and 1.2 mg/kg for BMS-753493 and BMS-748285, respectively) into the tumor-bearing CD2F1 mice (n¼ 9 in each treatment; n ¼3 at each time point). BMS-753493 and BMS-748285 dosing solutions were prepared as described in the previous section. The blood samples were collected at 2, 6, and 24 h post dose by direct cardiac puncture using vacutainers containing K 3 EDTA as an anticoagulant and 250 mmol/L phenylmethylsulphonylfluoride (PMSF)/ methyl acrylate (1:1, v/v) as an stabilizer cocktail. The volume ratio of stabilizer cocktail versus blood was 1:50. Blood was centrifuged at 2000 Â g for 5 min at 4 1C to obtain plasma, which was frozen immediately and stored at -20 1C until analyzed. Kidney, heart, and tumor tissue samples were collected and weighed, and were then frozen and stored at -70 1C until LC-MS/MS analysis.
Determination of test compounds by LC-MS/MS
The concentration of test compounds in plasma, heart, kidney, and tumors were determined by LC-MS/MS, as described as below. 3 μm, Phenomenex, Torrance, CA, USA) maintained at ambient temperature. Mobile phase A was water containing 10 mmol/L ammonium formate and 1.0% formic acid. Mobile phase B was 10 mmol/L ammonium formate and 1.0% formic acid in acetonitrile:water (90:10, v/v). HPLC flow rate was 0.3 mL/min and a linear gradient was run from 15% B at 0 min to 70% B at 2 min, held for 1 min and ramped back to 15% in 0.1 min. The total run time was 4 min. For each run, the flow from 1.2 to 2.2 min was delivered to the mass spectrometer. The rest was diverted to waste while a make-up flow consisting of 10 mmol/L ammonium formate and 1.0% formic acid in 11:9 (v/v) water: acetonitrile was delivered to mass spectrometer with a flow rate of 0.3 mL/ min. The HPLC was interfaced with an API 4000 mass spectrometer equipped with an electrospray ionization source in the positive ion mode. The Turbospray probe temperature was 500 1C and the spray voltage was 4000 V. Ultra high purity nitrogen was used as the Gas 1, Gas 2, curtain gas and collision gas at flow rates of 30, 60, 30 and 12 (arbitrary unit), respectively. Multiple reactions monitoring (MRM) was used for detection. For BMS-753493 and its internal standard, the parent ions were the doubly charged ion [Mþ2H] 
Statistical analysis
Paired Student's t-test was used for comparison of mean cold BMS-748285 levels in various tumors and tissues.
Results

QWBA after administration of [ 3 H]BMS-753493
The radioactivity was well visualized and quantified by whole body autoradiography in the tumor-bearing mice. Fig. 2 H]BMS-753493-derived radioactivity was extensively distributed in a large variety of normal tissues with the highest concentrations in the gastrointestinal tract/content, liver, kidney, heart and bone marrow. Very little radioactivity was observed in the brain and spinal cord ( Fig. 2 and Table 1 ). Interestingly, most of the radioactivity in the tumors was observed in the peripheral region and essentially no radioactivity in the core of tumors, indicating that the drug was not well perfused in the tumors (Fig. 3) . Because of the heterogeneous distribution, the radioactivity in tumors was calculated from the peripheral region only.
The uptake into the FR overexpressing tumor 98M109 was greater than that in M109 tumors at all time intervals despite of only 3.4-to 4.5-fold difference in radioactivity from [ 3 H]BMS-753493 observed (Fig. 3 and H]BMS-748285. The tissues that had the highest radioactivity were the intestinal tract/ content, liver, kidney, heart, bone marrow and tumors. Very little radioactivity was observed in the brain and spinal cord (Fig. 4 and Table  1 ). Likewise, heterogeneous distribution of [ 3 H]BMS-748285 derived radioactivity was observed in both FRþ and FR-tumor tissues, indicating that the drug was not well perfused in the tumors (Fig. 3) 
Pharmacokinetics and tissue distribution after intravenous dosing of unlabeled BMS-753493 and BMS-748285
BMS-753493 was cleared rapidly from circulation, and it was detected in plasma at 2 h but not later time points after i.v. injection of the drug. In contrast to BMS-753493, BMS-748285 converted from the conjugate was detectable through 24 h post dose (Fig. 5) . The plasma levels of BMS-748285 after i.v. administration of BMS-753493 were significantly less than those after i.v. administration of the equal molar BMS-748285 (AUC of BMS-748285: 245.9 and 645.1 ng Á h/mL, C 24-h : 3.2 and 13.5 ng/mL; Tables 2 and 3 ).
The concentrations of BMS-748285 in the tumors, heart and kidney were measured by LC-MS/MS. The levels of BMS- 
Discussion
One of the greatest challenges of anti-cancer treatment involves the delivery of therapeutically active levels of drug to tumors while not eliciting toxicity in non-tumor tissue. Selective drug targeting has long been a goal of drug development and there have been numerous investigations aimed at developing more efficient systems for the site specific delivery of drugs. This strategy has recently garnered great excitement in the oncology community with impressive clinical benefits reported on antibody directed cytotoxic drugs including T-DM1 and SGN-35 [13] [14] [15] . There were also considerable efforts to take advantage of specific folate receptors on the cancer cell surface by conjugation of folate with highly potent anti-cancer drugs for efficient delivery 5, 16 . 99Tc-EC20, a folate-targeted imaging agent, is in development for the diagnosis and identification of patients with FRþ tumors 17 . Clinical study involving greater than 100 patients indicated that there is marked selective uptake of 99Tc-EC20 in ovarian, renal, and pituitary tumors, reflecting the potential for therapeutic response through folate-targeted therapy 18 . The clinical proof-of-concept for FRtargeted efficacy of EC145, a conjugate of folic acid and desacetylvinblastine hydrazide, has been reported recently 19 . EC145 and pegylated liposomal doxorubicin (PLD) showed a statistically significant delay in progression-free survival over standard therapy in women with platinum-resistant ovarian cancer.
BMS-753493 contains a folate moiety and a potent epothilone analog, BMS-748285, attached through a peptide linker. It is designed to enable tumor-specific delivery of the highly cytotoxic epothilone analog BMS-748285 to its site of action, resulting in the blockade of cells in mitosis and eventual cell death. The choice of the epothilone as "cytotoxic warhead" in the target-delivery approach is considered ideal because the mechanism of action of epothilones (microtubule stabilization) is validated as capable of producing clinical benefits [20] [21] [22] . In addition, the selective cytotoxicity of epothilones against proliferating relative to non-proliferating cells (except neurons) reduces the likelihood of receptor-mediated normal tissue toxicity in those tissues that do express FR. Lack of FR expression in neurons reduces the likelihood of neuropathy, which is a key dose-limiting toxicity specific to this class of cytotoxic agents 23, 24 . Finally, the molecular potency of BMS-748285 (IC 50 o1 nmol/L) maximizes the potential to effect cell kill with the delivery of a limited number of drug molecules 12 .
In this study, we demonstrated modestly selective uptake and retention of BMS-753493 and BMS-748285 in FR-postive 98M109 tumors over FR-negative M109 tumors and normal tissues after administration of the folate-epothilone conjugate. This conclusion 
Conclusions
In summary, this study has demonstrated that BMS-753493, an epothilone folate conjugate, preferentially distributed the active epothilone into FR over-expressing 98M109 tumor over FRnegative tumors and tissues, compared to epothilone administration. The epothilone folate conjugate reduced systemic exposure to free epothilone and decreased cellular penetration into FR-negative tumors and tissues. The preferential distribution implies the folate conjugate might improve therapeutic margin in the treatment of tumors over-expressing folate receptors.
